Background: The activated clotting time (ACT) has been reported to be sensitive to the anticoagulant activity of the low-molecular weight heparin dalteparin following intravenous (IV) administration.
Objective: To evaluate the feasibility of an ACT-guided dalteparin dose adjustment strategy during percutaneous coronary intervention (PCI).
Methods: This was a retrospective study of 104 consecutive patients who underwent PCI using an ACT-guided strategy of IV dalteparin.